QURE

Beyond's analysis on QURE

• 2026-09-30 — SueWallSt alerts investors to a potential securities-law probe into uniQure after its Huntington's disease trial data disappointed, sending QURE shares lower

Recent news mentioning QURE

• 2026-09-30 — uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
• 2026-09-29 — uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

Appears alongside

• SueWallSt

Browse the full archive →